Published in Int J Clin Exp Pathol on January 01, 2008
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun (2013) 0.98
The first draft of the endostatin interaction network. J Biol Chem (2009) 0.98
Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells. Biochem J (2010) 0.94
Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm (Vienna) (2012) 0.91
Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PLoS One (2014) 0.91
Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells. J Neurochem (2009) 0.87
Emerging roles of sumoylation in the regulation of actin, microtubules, intermediate filaments, and septins. Cytoskeleton (Hoboken) (2015) 0.83
Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. J Biol Chem (2009) 0.83
Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J Alzheimers Dis (2009) 0.81
N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells. J Alzheimers Dis (2010) 0.81
Transglutaminase activation in neurodegenerative diseases. Future Neurol (2009) 0.79
Cellular factors modulating the mechanism of tau protein aggregation. Cell Mol Life Sci (2015) 0.79
Medical bioremediation of age-related diseases. Microb Cell Fact (2009) 0.76
Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models. Sci Rep (2016) 0.75
Effect of Some Growth Factors on Tissue Transglutaminase Overexpression Induced by β-Amyloid in Olfactory Ensheathing Cells. Mol Neurobiol (2016) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science (1987) 5.06
Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A (1986) 4.26
Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry (2003) 3.87
Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (2003) 3.76
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology (2000) 3.61
Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J (1991) 3.56
Transglutaminases: nature's biological glues. Biochem J (2002) 3.42
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging (1992) 3.05
Transglutaminases. Mol Cell Biochem (1984) 2.97
Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci (2002) 2.80
Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem (1986) 2.54
Head injury and the risk of AD in the MIRAGE study. Neurology (2000) 2.34
The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging (2000) 2.30
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol (1998) 2.19
Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A (2002) 2.15
Alzheimer's disease: immunoreactivity of neurofibrillary tangles with anti-neurofilament and anti-paired helical filament antibodies. Brain Res (1984) 1.98
Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett (2001) 1.82
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res (2000) 1.74
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci (2006) 1.68
Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost (1994) 1.63
Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci U S A (1982) 1.63
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. J Neuropathol Exp Neurol (1999) 1.55
Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J (1999) 1.53
The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. Neuroscience (2001) 1.51
Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol (2001) 1.48
Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol (2002) 1.44
Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem (1999) 1.44
Differential expression of tissue transglutaminase in human cells. An immunohistochemical study. Cell Tissue Res (1989) 1.44
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40
Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol (1994) 1.37
Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry (1995) 1.35
Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev (2000) 1.34
Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence. Biochemistry (1988) 1.34
Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J (2005) 1.33
Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. Proc Natl Acad Sci U S A (1990) 1.31
Tissue transglutaminase: an enzyme with a split personality. Int J Biochem Cell Biol (1999) 1.31
The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res (2004) 1.31
Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience (2003) 1.29
Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. Brain Res Brain Res Rev (2005) 1.26
Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res (1997) 1.24
Epidemiology of clinically diagnosed Alzheimer's disease. Ann Neurol (1986) 1.24
Repeated mild brain injuries result in cognitive impairment in B6C3F1 mice. J Neurotrauma (2002) 1.23
Chemical relationship of the paired helical filaments of Alzheimer's dementia to normal human neurofilaments and neurotubules. Brain Res (1978) 1.21
Tissue transglutaminase and the stress response. Amino Acids (2007) 1.21
Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging (1997) 1.20
Transglutaminase 2 in inflammation. Front Biosci (2006) 1.20
Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis (2002) 1.18
The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. Biochemistry (1997) 1.18
Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res (1994) 1.15
Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol (2000) 1.14
Head injury as a risk factor in Alzheimer's disease. Brain Inj (1995) 1.14
A monoclonal antibody that recognizes a phosphorylated epitope in Alzheimer neurofibrillary tangles, neurofilaments and tau proteins immunostains granulovacuolar degeneration. Acta Neuropathol (1987) 1.13
Transglutaminases in disease. Neurochem Int (2002) 1.13
The deduced sequence of the novel protransglutaminase E (TGase3) of human and mouse. J Biol Chem (1993) 1.13
Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J Biol Chem (2000) 1.13
Highly active soluble processed forms of the transglutaminase 1 enzyme in epidermal keratinocytes. J Biol Chem (1995) 1.12
Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci (1996) 1.11
Tissue transglutaminase is increased in Huntington's disease brain. J Neurochem (1999) 1.10
Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost (1996) 1.08
Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int (2002) 1.06
Alzheimer's disease: exposure of neurofilament immunoreactivity in SDS-insoluble paired helical filaments. Brain Res (1984) 1.06
Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurol (2001) 1.05
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J (2004) 1.05
Cardiovascular disease and risk of Alzheimer's disease. Neurol Res (2006) 1.04
Traumatic brain injury: cause or risk of Alzheimer's disease? A review of experimental studies. J Neural Transm (Vienna) (2005) 1.03
C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity. J Biol Chem (1996) 1.02
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer beta/A4 amyloid protein by transglutaminase. FEBS Lett (1993) 1.01
Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J (1995) 0.99
Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem (1997) 0.98
Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases. Amino Acids (2004) 0.98
Human erythrocyte membrane protein band 4.2 (pallidin). Semin Hematol (1993) 0.98
Androgens, aging, and Alzheimer's disease. Endocrine (2006) 0.98
Traumatic brain injury causes delayed motor and cognitive impairment in a mutant mouse strain known to exhibit delayed Wallerian degeneration. J Neurosci Res (1998) 0.98
Brain aging and Alzheimer's disease; use it or lose it. Prog Brain Res (2002) 0.96
Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis. FASEB J (1999) 0.95
Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem (1999) 0.95
Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets (2004) 0.95
Tissue-transglutaminase in rat and human brain: light and electron immunocytochemical analysis and in situ hybridization study. Brain Res Bull (2001) 0.95
Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J Alzheimers Dis (2006) 0.95
Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J Neurochem (1993) 0.95
Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C. J Biol Chem (1995) 0.94
Identification of glutamine and lysine residues in Alzheimer amyloid beta A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to alpha 2M receptor. FEBS Lett (1994) 0.94
Transglutaminase cross-linking of the tau protein. J Neurochem (1995) 0.93
Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injury. Neuroreport (1994) 0.92
Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann N Y Acad Sci (2000) 0.92
Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ (1999) 0.92
Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol (2003) 0.92
Cloning and expression of chicken erythrocyte transglutaminase. Proc Natl Acad Sci U S A (1992) 0.91
Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia. Neurosci Lett (2004) 0.91
Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res (1999) 0.90
Emergence of immunoreactivities for phosphorylated tau and amyloid-beta protein in chronic stage of fluid percussion injury in rat brain. Neuroreport (1998) 0.90
Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp Neurol (2000) 0.90
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc Natl Acad Sci U S A (2003) 2.82
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol (2007) 2.75
Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol (2007) 2.68
A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol (2006) 2.57
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain (2009) 2.45
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation (2007) 2.43
Risk factors for dementia with Lewy bodies: a case-control study. Neurology (2013) 2.38
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol (2010) 2.20
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol (2011) 2.17
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17
Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet (2012) 2.07
Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord (2012) 2.02
Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol (2006) 2.02
Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02
Lrrk2 and Lewy body disease. Ann Neurol (2006) 2.00
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood (2008) 2.00
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
The peptidyl-prolyl isomerase Pin1 regulates the stability of granulocyte-macrophage colony-stimulating factor mRNA in activated eosinophils. Nat Immunol (2005) 1.99
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol (2013) 1.95
Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93
Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2004) 1.92
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90
Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol (2009) 1.89
Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol (2005) 1.85
TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord (2011) 1.73
Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol (2008) 1.72
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
The prolyl isomerase Pin1 acts as a novel molecular switch for TNF-alpha-induced priming of the NADPH oxidase in human neutrophils. Blood (2010) 1.68
In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-containing human brain specimens. Exp Neurol (2003) 1.68
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2003) 1.58
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
A critical role for Pin1 in allergic pulmonary eosinophilia in rats. J Allergy Clin Immunol (2007) 1.58
Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (2011) 1.57
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol (2014) 1.54
Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52
Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol (2013) 1.52
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51
Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol (2008) 1.49
Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol (2012) 1.48
Alpha-synuclein immunohistochemistry in two cases of co-occurring idiopathic Parkinson's disease and motor neuron disease. Mov Disord (2005) 1.48
Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem (2007) 1.47
TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol (2014) 1.47